Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Edmund Folefac"'
Autor:
Shihua Wang, Ming Yin, Peng Wang, Edmund Folefac, J. Paul Monk, Fred K. Tabung, Steven K. Clinton
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundRandomized controlled phase III trials have reported significant improvements in disease response and survival with the addition of chemotherapy to androgen deprivation therapy for men presenting with metastatic prostate cancer. We examined
Externí odkaz:
https://doaj.org/article/89aa1c27785549b887048c781609d16e
Autor:
Giuseppe Procopio, Prabhu Bhagavatheeswaran, Bernard Escudier, Chung-Han Lee, Shruti Shally Saggi, Suresh Nair, Ruth Perets, Michael A Carducci, Vincent Castonguay, Edmund Folefac, Sebastien J. Hotte, Wilson H Miller,, Heshani Desilva
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 11 (2022)
Background The role and sequencing of combination immuno-oncology (IO) therapy following progression on or after first-line IO therapy has not been well-established. The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION)
Externí odkaz:
https://doaj.org/article/b2458af932914c44a5e2518aa22ce139
Autor:
Carolyn J. Presley, Jessica L. Krok-Schoen, Sarah A. Wall, Anne M. Noonan, Desiree C. Jones, Edmund Folefac, Nicole Williams, Janine Overcash, Ashley E. Rosko
Publikováno v:
BMC Geriatrics, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background Evidence-based practice in geriatric oncology is growing, and national initiatives have focused on expanding cancer care and research to improve health outcomes for older adults. However, there are still gaps between knowledge and
Externí odkaz:
https://doaj.org/article/8dff91c7c2ee4fcc87bd0ef35cdd6753
Autor:
Ming Yin, Jing Zhao, Paul Monk, Douglas Martin, Edmund Folefac, Monika Joshi, Ning Jin, Amir Mortazavi, Claire Verschraegen, Steven Clinton
Publikováno v:
Cancer Medicine, Vol 9, Iss 1, Pp 27-34 (2020)
Abstract Background It remains controversial if radical prostatectomy or definitive radiation therapy produces equivalent outcomes in high‐risk localized prostate cancer. Methods We queried The Surveillance, Epidemiology, and End Results (SEER) dat
Externí odkaz:
https://doaj.org/article/a099340bfc314aa99143ce94364ea70a
Autor:
Sarah A. Wall, Ying Huang, Ashleigh Keiter, Allesia Funderburg, Colin Kloock, Nicholas Yuhasz, Tanya R. Gure, Edmund Folefac, Erin Stevens, Carolyn J. Presley, Nicole O. Williams, Jessica L. Krok-Schoen, Michelle J. Naughton, Ashley E. Rosko
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
The incidence of hematologic malignancies (HMs) is highest in the seventh decade of life and coincides with increasing occult, age-related vulnerabilities. Identification of frailty is useful in prognostication and treatment decision-making for older
Externí odkaz:
https://doaj.org/article/68d00d3fd3464be19f40aae47ee0e545
Autor:
Elizabeth Pan, Wanling Xie, Archana Ajmera, Arlene Araneta, Christina Jamieson, Edmund Folefac, Arif Hussain, Christos E. Kyriakopoulos, Adam Olson, Mamta Parikh, Rahul Parikh, Biren Saraiya, S. Percy Ivy, Eliezer M. Van Allen, Neal I. Lindeman, Bose S. Kochupurakkal, Geoffrey I. Shapiro, Rana R. McKay
Publikováno v:
Molecular Cancer Therapeutics. 22:511-518
Given that radium-223 is a radiopharmaceutical that induces DNA damage, and olaparib is a PARP inhibitor that interferes with DNA repair mechanisms, we hypothesized their synergy in metastatic castration-resistant prostate cancer (mCRPC). We sought t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd08ddb7e908aa341fa6a73a7134dded
https://doi.org/10.1158/1535-7163.mct-22-0583
https://doi.org/10.1158/1535-7163.mct-22-0583
Autor:
Vincent Vinh-Hung, Olena Gorobets, Gilles Natchagande, Paul Sargos, Ming Yin, Nam P. Nguyen, Claire Verschraegen, Edmund Folefac
Publikováno v:
Clinical Genitourinary Cancer. 20:e473-e484
Background Enzalutamide is an important drug in the treatment of prostate cancer. Standard dosing often requires dose reduction because of side effects. There is no information on survival outcomes with lower doses. We investigated the impact of star
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a113c7420115f57b2633559bc6e52f1
https://doi.org/10.1016/j.clgc.2022.05.012
https://doi.org/10.1016/j.clgc.2022.05.012
Autor:
Samuel A. Funt, Michael Lattanzi, Karissa Whiting, Hikmat Al-Ahmadie, Colleen Quinlan, Min Yuen Teo, Chung-Han Lee, David Aggen, Danielle Zimmerman, Deaglan McHugh, Arlyn Apollo, Trey D. Durdin, Hong Truong, Jeffrey Kamradt, Maged Khalil, Bradley Lash, Irina Ostrovnaya, Asia S. McCoy, Grace Hettich, Ashley Regazzi, Marwah Jihad, Neha Ratna, Abigail Boswell, Kaitlyn Francese, Yuanquan Yang, Edmund Folefac, Harry W. Herr, S. Machele Donat, Eugene Pietzak, Eugene K. Cha, Timothy F. Donahue, Alvin C. Goh, William C. Huang, Dean F. Bajorin, Gopa Iyer, Bernard H. Bochner, Arjun V. Balar, Amir Mortazavi, Jonathan E. Rosenberg
Publikováno v:
J Clin Oncol
PURPOSE Neoadjuvant gemcitabine and cisplatin (GC) followed by radical cystectomy (RC) is standard for patients with muscle-invasive bladder cancer (MIBC). On the basis of the activity of atezolizumab (A) in metastatic BC, we tested neoadjuvant GC pl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::611a8910c42cbcab86adb0b2211563d4
https://pubmed.ncbi.nlm.nih.gov/35609220
https://pubmed.ncbi.nlm.nih.gov/35609220
Autor:
Rana R. McKay, Geoffrey I. Shapiro, Bose S. Kochupurakkal, Neal I. Lindeman, Eliezer M. Van Allen, S. Percy Ivy, Biren Saraiya, Rahul Parikh, Mamta Parikh, Adam Olson, Christos E. Kyriakopoulos, Arif Hussain, Edmund Folefac, Christina Jamieson, Arlene Araneta, Archana Ajmera, Wanling Xie, Elizabeth Pan
Given that radium-223 is a radiopharmaceutical that induces DNA damage, and olaparib is a PARP inhibitor that interferes with DNA repair mechanisms, we hypothesized their synergy in metastatic castration-resistant prostate cancer (mCRPC). We sought t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61af91d0ca62d1a64e8f73b770de4f1b
https://doi.org/10.1158/1535-7163.c.6534781.v1
https://doi.org/10.1158/1535-7163.c.6534781.v1
Prostate cancer is common in countries with affluent dietary patterns and represents a heterogeneous collection of subtypes with varying behavior. Reductionist strategies focusing on individual nutrients or foods have not clearly defined risk factors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ed7e6bd2178a013d2f823acdfa4c4e7
https://doi.org/10.1158/1940-6207.c.6547070
https://doi.org/10.1158/1940-6207.c.6547070